AB-729
AB-729 is a GalNAc-conjugated RNAi therapeutic designed for targeted hepatocyte delivery via the ASGR receptor. It demonstrates potent suppression of HBV replication and antigen reduction in both in vitro and in vivo studies, supporting its investigation for chronic hepatitis B treatment.
Product Specifications
CAS Number
2634739-74-3
Storage Conditions
-20°C
Notes
For research use only.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog